RxDoctor Payments Data

Marcee Wharton

Physician Assistant · Mesa, AZNPI 1760442784

Payments from drug & device makers

$2,277in general payments, 2019–2025

Across 141 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$314
  • Novo Nordisk$271
  • Boehringer Ingelheim$255
  • AbbVie$181
  • Amarin Pharma, Inc.$120
  • Sunovion Pharmaceuticals Inc.$115
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,19796%
  • Education$804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,277 in reported general payments places this provider in the 80th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$74,455
Medicare patients
263
Services billed
783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$85,682
JardianceEmpagliflozin67$70,169
AtivanLorazepam12$43,169
MyrbetriqMirabegron44$39,994
FarxigaDapagliflozin Propanediol36$37,974
MounjaroTirzepatide27$35,665
TrulicityDulaglutide22$33,608
JanuviaSitagliptin Phosphate21$17,179
RybelsusSemaglutide20$16,554
EliquisApixaban13$16,397
Tresiba Flextouch U-100Insulin Degludec20$13,005
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,957
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$7,097
Atorvastatin Calcium583$4,366
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$3,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$271$102,23696 claims
Boehringer IngelheimJardiance$255$70,16967 claims
Lilly USA, LLCMounjaro, Trulicity$100$69,27349 claims
Astellas Pharma US IncMyrbetriq$314$39,99444 claims
AstraZenecaFarxiga$64$37,97436 claims
MerckJanuvia$38$17,17921 claims
PfizerEliquis$68$16,39713 claims
GSKTrelegy Ellipta$63$9,95711 claims
AbbVieSynthroid$181$2,28426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →